Forest Labs Aims To Launch Once-Daily Namenda Ahead Of Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Alzheimer's line-extension is in Phase III, and first ANDA with paragraph IV certification for current twice-daily formula could be filed next fall.